Hemato

Scope & Guideline

Exploring Breakthroughs in Blood Health

Introduction

Welcome to your portal for understanding Hemato, featuring guidelines for its aims and scope. Our guidelines cover trending and emerging topics, identifying the forefront of research. Additionally, we track declining topics, offering insights into areas experiencing reduced scholarly attention. Key highlights include highly cited topics and recently published papers, curated within these guidelines to assist you in navigating influential academic dialogues.
LanguageEnglish
ISSN-
PublisherMDPI
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationHEMATO-BASEL / Hemato
Frequency4 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressST ALBAN-ANLAGE 66, CH-4052 BASEL, SWITZERLAND

Aims and Scopes

The journal 'Hemato' primarily focuses on advancing knowledge in the field of hematology through innovative research, clinical studies, and comprehensive reviews. It emphasizes the diagnosis, treatment, and management of hematologic diseases, with a particular attention to novel therapies and patient outcomes.
  1. Hematologic Malignancies:
    A core area of focus is on hematologic malignancies, including various forms of leukemia, lymphoma, and myeloma. The journal publishes research on their molecular mechanisms, treatment strategies, and clinical outcomes.
  2. Transfusion Medicine:
    The journal covers advancements in transfusion medicine, exploring the implications of blood component therapies and their interactions with different treatment modalities, particularly in patients with hematologic disorders.
  3. Innovative Therapies and Technologies:
    There is a strong emphasis on innovative therapies, including immunotherapies, CAR-T cell therapies, and targeted therapies. The journal showcases studies that evaluate the efficacy and safety of these novel treatment approaches.
  4. Clinical and Epidemiological Research:
    The journal publishes clinical and epidemiological studies that provide insights into the prevalence, risk factors, and outcomes of hematologic diseases, contributing to evidence-based practice.
  5. Patient-Centered Care:
    Research on the psychosocial aspects of hematologic diseases, including patient-reported outcomes and quality of life, is also a significant focus, reflecting a commitment to patient-centered care.
The journal 'Hemato' has witnessed a rise in certain themes and areas of research, reflecting the dynamic nature of hematology. These trending and emerging scopes highlight the journal's responsiveness to current challenges and advancements in the field.
  1. Precision Medicine and Genomics:
    There is a growing emphasis on precision medicine and the integration of genomic data into treatment strategies for hematologic diseases, which is crucial for tailoring therapies to individual patient profiles.
  2. Artificial Intelligence and Big Data:
    Emerging research on the application of artificial intelligence and big data analytics in hematology is trending, with studies focusing on predictive modeling and improving diagnostic accuracy.
  3. Immunotherapy Developments:
    The journal has seen an increase in publications related to immunotherapy, particularly CAR-T cell therapy and checkpoint inhibitors, as these modalities continue to revolutionize treatment paradigms.
  4. Management of Comorbidities in Hematologic Patients:
    Research addressing the management of comorbidities, such as cardiovascular issues in patients with hematologic malignancies, is gaining traction, reflecting a holistic approach to patient care.
  5. Global Health Initiatives in Hematology:
    There is an emerging focus on global health initiatives and resource-limited settings, particularly studies aimed at improving care for populations with high burdens of hematologic diseases.

Declining or Waning

As the field of hematology evolves, certain themes and areas of focus within the journal 'Hemato' appear to be declining. This may reflect shifts in research priorities or advancements in treatment that render some topics less relevant.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decline in publications focused on traditional chemotherapy approaches for hematologic malignancies, as newer targeted therapies and immunotherapies gain prominence.
  2. Historical Epidemiological Studies:
    Studies that primarily focus on historical epidemiological data without integrating new findings or technologies are less frequently published, indicating a shift towards more current and actionable research.
  3. Basic Science Research Without Clinical Application:
    Basic science studies that do not demonstrate a clear clinical application or relevance to patient care are becoming less common, as the journal increasingly prioritizes translational research.

Similar Journals

Journal of Blood Medicine

Connecting Minds: Bridging Research and Clinical Practice in Hematology
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-2736Frequency: 1 issue/year

The Journal of Blood Medicine, published by DOVE MEDICAL PRESS LTD, stands as a vital resource in the field of hematology, focusing on the latest research developments and clinical advancements in blood medicine. With an impact factor reflective of its growing relevance, this open-access journal has been delivering quality scholarly work since 2010, ensuring that critical research is readily available to the global scientific community. The journal operates under an open-access model, further enhancing its dissemination and accessibility to researchers, professionals, and students alike. In the 2023 rankings, it secured a Q3 category status within hematology and achieved a commendable 76th rank out of 137 in Scopus listings, indicating its commitment to quality and innovation in this specialized area. Located in New Zealand, the journal's diverse topics encompass clinical research, treatment modalities, and emerging therapies, contributing significant insights vital for shaping future advancements in blood medicine.

EUROPEAN JOURNAL OF HAEMATOLOGY

Exploring the Frontiers of Hematological Science
Publisher: WILEYISSN: 0902-4441Frequency: 12 issues/year

EUROPEAN JOURNAL OF HAEMATOLOGY, published by Wiley, serves as a vital resource for experts in the field of hematology, focusing on the latest advancements in blood disorders and therapies. With an ISSN of 0902-4441 and an E-ISSN of 1600-0609, this esteemed journal has been disseminating knowledge since 1986 and continues to thrive, converging its visionary approach through to 2024. Notably, it holds a distinguished Q2 ranking in Hematology and an impressive Q1 ranking in the broader category of Medicine (miscellaneous) as of 2023, highlighting its significant contribution to the scientific community. With a Scopus rank of #45/137 and a 67th percentile in the field, the journal is recognized for its rigorous peer-reviewed research, making it an indispensable publication for researchers, practitioners, and students aiming to stay at the forefront of hematological studies. Though not an open-access journal, it ensures broad accessibility to critical findings via its subscription model, thus fostering an informed and globally engaged audience.

TRANSFUSION MEDICINE AND HEMOTHERAPY

Empowering innovation in hematology and transfusion medicine.
Publisher: KARGERISSN: 1660-3796Frequency: 6 issues/year

TRANSFUSION MEDICINE AND HEMOTHERAPY, published by KARGER, is a prominent journal dedicated to advancing the fields of hematology and transfusion medicine. With an ISSN of 1660-3796 and E-ISSN 1660-3818, this esteemed journal has been a valuable resource for researchers and clinicians since its inception in 1973, with significant publication phases continuing into 2024. It currently holds a Q2 ranking in Hematology and a Q3 ranking in Immunology and Allergy, reflecting its impact and relevance in these critical fields. The journal features original articles, reviews, and clinical studies, presenting cutting-edge research that aids in the development of effective therapies and enhances patient care. Open access options are available, ensuring that crucial findings are accessible to a broad audience. As an important platform for dialogue and advancement in transfusion science, TRANSFUSION MEDICINE AND HEMOTHERAPY supports the global health community's efforts to improve treatment outcomes and foster innovation in medical practices.

Egyptian Journal of Haematology

Pioneering Knowledge in Hematologic Malignancies and Care
Publisher: WOLTERS KLUWER MEDKNOW PUBLICATIONSISSN: 1110-1067Frequency: 4 issues/year

The Egyptian Journal of Haematology, published by WOLTERS KLUWER MEDKNOW PUBLICATIONS, stands as a pivotal resource in the field of hematology, particularly within the context of Egypt and the broader Middle Eastern region. This journal is dedicated to disseminating high-quality research that explores the latest advancements in blood disorders, hematologic malignancies, and transfusion medicine. With a focus on original research, case studies, and reviews, it aims to provide a comprehensive platform for hematologists, researchers, and healthcare professionals to enhance their understanding and management of hematological conditions. Although it is not an open-access journal, the rigorous peer-review process ensures that only the most impactful studies are published, contributing to the journal's reputation in the academic community. The Egyptian Journal of Haematology serves as an essential tool for advancing knowledge, improving clinical outcomes, and fostering collaboration among experts in the field.

Hematologie

Exploring Innovations in Hematology
Publisher: JOHN LIBBEY EUROTEXT LTDISSN: 1264-7527Frequency: 6 issues/year

Hematologie is a highly regarded journal in the field of hematology, published by JOHN LIBBEY EUROTEXT LTD. With an ISSN of 1264-7527 and an E-ISSN of 1950-6368, this journal has established itself as a vital resource for researchers, clinicians, and students dedicated to advancing the understanding of blood disorders and treatments. Although the journal's coverage in Scopus was discontinued in 2018, it has continually provided invaluable insights and research findings. The journal aims to foster knowledge sharing and discussion in hematology, exploring innovative methodologies and emerging trends in the field. With a commitment to quality research, Hematologie remains an essential platform for disseminating critical findings that can drive clinical practice and influence future studies in hematological sciences.

INTERNATIONAL JOURNAL OF HEMATOLOGY

Unveiling Innovations in Hematology
Publisher: SPRINGER JAPAN KKISSN: 0925-5710Frequency: 12 issues/year

The INTERNATIONAL JOURNAL OF HEMATOLOGY, published by SPRINGER JAPAN KK, serves as a critical platform for advancing research in the field of hematology. With a prestigious history spanning over three decades from 1991 to 2024, this journal is recognized for its impactful contributions, evidenced by its Q2 category ranking in Hematology for 2023, and its notable position at rank #71 out of 137 in the Scopus Medicine Hematology category. Researchers and professionals within the hematology community benefit from the journal's rigorous peer-reviewed articles that cover a wide range of topics, including clinical studies, basic research, and novel therapeutic strategies. Though currently non-open access, it provides essential insights and findings to an audience passionate about the latest advancements in blood disorders and treatments. Situated in Japan, the journal not only showcases high-quality research but also fosters a global exchange of knowledge in hematology, making it a significant resource for scholars, practitioners, and students alike.

Hematology Transfusion and Cell Therapy

Innovating the future of blood disorder management.
Publisher: ELSEVIERISSN: 2531-1379Frequency: 4 issues/year

Hematology Transfusion and Cell Therapy, published by Elsevier, is a leading Open Access journal dedicated to advancing the fields of hematology, immunology, and transfusion medicine. Since its establishment in 2018, this journal has provided a vital platform for sharing innovative research and clinical advancements in the management of blood disorders and cellular therapies. Based in Brazil, it attracts a global audience, facilitating access to high-quality research that influences clinical practice and policy. With a current impact factor that places it in the Q3 category for both hematology and immunology as of 2023, the journal is recognized for its rigorous peer-review process and commitment to disseminating significant findings. By featuring a diverse range of articles, from original research to reviews, Hematology Transfusion and Cell Therapy aims to foster collaboration and knowledge sharing among researchers, professionals, and students alike, empowering them to tackle emerging challenges in their fields.

Journal of Clinical and Experimental Hematopathology

Transforming Knowledge into Clinical Practice.
Publisher: JAPANESE SOC LYMPHORETICULAR TISSUE RESEARCHISSN: 1346-4280Frequency: 4 issues/year

The Journal of Clinical and Experimental Hematopathology, published by the Japanese Society of Lymphoreticular Tissue Research, is a vital resource dedicated to advancing the field of hematopathology. With an impressive Open Access model since 2019, this journal provides researchers, clinicians, and students from around the world with unfettered access to cutting-edge research and developments in hematology and pathophysiology. Based in Japan, it has established a prominent reputation in the academic community, boasting a Q3 quartile ranking in Hematology and Q1 rankings in both Medicine (Miscellaneous) and Pathophysiology as of 2023. With its innovative contributions and high visibility, the journal not only fosters scholarly discourse but also impacts clinical practices, making it an essential publication for anyone interested in the complexities of hematologic disorders. For submissions and further inquiries, the journal is located at Nagoya University Graduate School of Medicine, Japan.

Blood Research

Unveiling Breakthroughs in Hematology for Global Impact
Publisher: SPRINGERISSN: 2287-979XFrequency: 4 issues/year

Blood Research, published by SPRINGER, is a premier journal dedicated to the multifaceted realm of hematology, serving as a crucial platform for disseminating innovative research findings and advancements in the diagnosis and treatment of blood-related disorders. With an ISSN of 2287-979X and an E-ISSN of 2288-0011, this journal is recognized for its commitment to scholarly excellence and impact in the field, currently holding a reputable Q2 ranking in the Hematology category as per the 2023 metrics. The journal spans from 2013 to 2024, providing a broad archive of quality research that is vital for researchers, healthcare professionals, and students alike. Although it is not an Open Access journal, it offers insightful contributions that enhance the understanding of hematological science, fostering the exchange of knowledge crucial for advancing patient care and clinical practices globally. The journal’s performance is underscored by its Scopus ranking in the 46th percentile, reflecting its significant role in the ongoing discourse in hematology.

Current Hematologic Malignancy Reports

Innovative Insights into Hematologic Malignancies
Publisher: CURRENT MEDICINE GROUPISSN: 1558-8211Frequency: 4 issues/year

Current Hematologic Malignancy Reports is a significant journal published by the CURRENT MEDICINE GROUP, dedicated to advancing the field of hematology and oncology. With an impressive categorization in the Q1 and Q2 quartiles reflecting its influence and quality—ranked 39th in Medicine Hematology and 129th in Medicine Oncology—it aims to provide a critical platform for the dissemination of innovative research and insights related to hematologic malignancies. Since its inception in 2006, this journal has served as a vital resource for researchers, clinicians, and students alike, fostering collaborative discussions and the exchange of knowledge that can drive improvements in patient care and treatment outcomes. The journal is not currently open-access, ensuring a curated selection of high-quality articles that are peer-reviewed for the enrichment of its readership. The address for correspondence is 400 Market Street, Ste 700, Philadelphia, PA 19106, United States. Its robust impact within the community is showcased through its competitive Scopus rankings, further establishing its importance in ongoing scientific discourse.